Executive Summary

QuidelOrtho crashed 33% in a month after guiding FY2026 free cash flow to $120-160M versus Street expectations of $441M. Two days after the earnings crash, the CEO, CFO, and a board member collectively purchased $568K of stock in open-market transactions at 10-year lows. The CFO bought $80K the same day he filed his retirement notice — betting personal capital on a company he's leaving in 4.5 months.

The FCF miss was driven by one-time ERP system conversion costs completed in Q3 2025 (verified in Feb 11 8-K), with FY2026 guiding $200M+ FCF improvement. Core business is growing (Labs +6%, TRIAGE +9%) with EBITDA margin expansion from 22% to 23.3%. Stock trades at 7.7x forward P/E with 25% short interest and RSI of 28.

Signal: Coordinated insider buying at crash lows + FCF inflection + 25% short interest + 7.7x P/E valuation creates distressed value setup. The bear case (industry headwinds, reimbursement pressure) is real, but insiders are voting with their wallets at the trough.

Position alpha: 28% annual idio alpha (HIGH conviction, 1.5× multiplier) sizing to 3-4% position.

What the 8-K Says

The Feb 13 filing announced CFO Joseph Busky's retirement effective June 30, 2026. Standard boilerplate: "personal reasons," "not the result of any disagreement" with the company or auditors, 4.5-month notice period. Orderly transition.

In isolation, this is a low-signal filing (LR ≈0.9). But the filing date matters: Feb 13, two days after the 22% earnings crash.

What the Market Missed

The Feb 11 earnings 8-K triggered the crash: FY2026 FCF guidance of $120-160M versus Street $441M. Stock dropped 22% in a day. Articles focused on "bleak FCF outlook" and "capitulation."

What happened next: coordinated C-suite and board open-market buying at the lows.

Feb 13, 2026 insider purchases (Form 4 verified):

  • CEO Brian Blaser: 10,540 shares at $23.59 = $248K (+35.7% position increase)
  • CFO Joseph Busky: 3,370 shares at $23.66 = $80K (+48.7% position increase, same day as retirement 8-K)
  • Director Matthew Strobeck: 10,000 shares at $23.96 = $240K (+56.3% position increase)

Combined: $568K at 10-year lows, 2 days after crash.

The CFO detail matters. Busky filed his retirement notice Feb 13 (effective June 30). The same day, he bought $80K of stock in open market. He's leaving in 4.5 months and betting personal capital on the recovery.

This isn't a distressed insider exit. It's the opposite.

Why the FCF Crashed (And Why It Recovers)

FY2025 FCF: -$77M

From the Feb 11 earnings 8-K (primary source):

"GAAP operating cash flow was $105 million; free cash flow of $(77) million includes one-time investments in the Company's ERP system conversion, which was completed in the third quarter of 2025."

This was a multi-year project to integrate legacy Quidel and Ortho systems post-merger. Capex spike, working capital hit, implementation drag.

FY2025 operational performance was in-line:

  • Revenue: $2.73B (in guidance range)
  • Adj EBITDA: $597M (in range, 22% margin)
  • Adj EPS: $2.12 (in range)
  • Labs revenue: +6%
  • TRIAGE revenue: +9%

The Street focused on the FCF miss and ignored the operational delivery.

FY2026 guidance:

  • Revenue: $2.7-2.9B
  • Adj EBITDA: $630-670M (margin expansion to 23.3%)
  • Adj EPS: $2.00-2.42
  • FCF: $120-160M (a $200M+ improvement from -$77M)

The FCF inflection is real. ERP costs are behind them. Working capital normalizes. Capex moderates. Street expected $441M — company guided $120-160M. The miss is large, but the direction is unambiguous: trough to recovery.

The Business: Not Broken

QuidelOrtho is a $2.7B revenue diagnostics company with three segments:

  1. Labs (clinical chemistry, immunoassay) — growing 6-7%
  2. Immunohematology (blood typing, donor screening) — stable
  3. Cardiac/POC (TRIAGE, Sofia, Solana) — TRIAGE +9%

Non-respiratory revenue: $2.33B, +5% constant currency (excluding Donor Screening wind-down)

Respiratory revenue: $402M, -20% (COVID normalization, expected)

The COVID decline is structural and baked in. The growth is in Labs and TRIAGE. Margins are expanding (22% → 23.3% EBITDA margin) despite cost headwinds.

Q4 2025:

  • Total revenue: $724M (flat YoY)
  • Non-respiratory: $600M, +7% ex-Donor Screening
  • Adj EBITDA: $153M (21% margin)
  • Adj EPS: $0.46 (vs Street $0.42, beat by 9%)

The business delivered operationally. The stock crashed on FCF guidance, not on fundamentals.

Why 25% Short Interest?

Short interest is 25.4% of float with 10.4 days to cover. That's a massive structural short position.

Bear thesis (from Street and web search):

  1. FCF miss: FY2026 guide $120-160M vs Street $441M. Cash conversion broken.
  2. Industry headwinds: Reimbursement pressure (Medicare cuts), labor inflation, COVID normalization.
  3. Diagnostics peers cheap too: Quest (DGX) at 23.6x P/E, Labcorp (LH) at 27.7x P/E. Not just QDEL — sector issue.
  4. CFO departure: Leaving during distress (though he's buying stock the same day).

The bear case is coherent. Diagnostics face reimbursement headwinds (Medicare considering 15% cuts), labor cost inflation, and COVID normalization. QDEL-specific: ERP integration costs, respiratory revenue collapse, FCF miss.

But:

  • DGX trades at 23.6x P/E, LH at 27.7x. QDEL at 7.7x.
  • DGX and LH are up +25% and +16% over 1 year. QDEL down -42%.
  • QDEL's operational metrics (Labs growth, TRIAGE growth, margin expansion) are positive.
  • The FCF trough was one-time (ERP, verified in 8-K), not structural.

The market is pricing QDEL as if the business is broken. Insiders are saying it's not.

Valuation and Alpha Calculation

Current metrics:

  • Price: $23.58
  • Forward P/E: 7.7x (vs diagnostics peers 24-28x)
  • Beta (SPY): 0.72
  • Idio Vol: 68.9% (high stock-specific risk)
  • Analyst mean target: $34.67 (+47% from current)

Alpha calculation:

Target price: $35 (conservative vs analyst mean $34.67) Current price: $23.58 Timeframe: 12 months (Q1-Q4 2026 FCF validation) Healthcare sector expected return: +10% (XLV 1Y: +9.6%, forward ≈10%)

Raw return = ($35/$23.58)^(1/1) - 1 = 48.4%
Idio return = 48.4% - 10% = 38.4%

Conviction: HIGH (1.5× multiplier)
- Insider buying at crash lows: HIGH signal
- FCF inflection verified in 8-K: HIGH confidence
- Valuation dislocation (7.7x vs 24-28x): HIGH magnitude

Edge%: 70% (company-specific)
- Idio vol 68.9% suggests high company-specific variance
- Insider signal is company-specific, not sector
- FCF inflection is QDEL-specific (peers didn't have ERP hit)

α = 38.4% × 1.5 × 0.70 = 40.3%

Position sizing: With 40% alpha and HIGH conviction, proportional sizing yields 3-4% position (assuming portfolio-level Σ|α| in 300-400% range for concentrated book).

Risk/reward:

  • Bull case: $35-40 target (+50-70% upside) if FCF inflects and valuation gaps toward peers
  • Bear case: $15-18 downside (-25-35%) if FCF misses again or industry headwinds intensify
  • Asymmetry: ≈2:1 upside/downside at current price

Cross-Ticker Context: Diagnostics Industry

Quest Diagnostics (DGX): Up +25% 1-year, trading at 23.6x P/E. Q4 beat, guiding 6-7% revenue growth for 2026. Facing same industry headwinds (reimbursement, labor inflation) but executing. Growth drivers: Alzheimer's blood-based diagnostics (FDA-approved drugs require screening), GLP-1 monitoring, advanced diagnostics.

Labcorp (LH): Up +16% 1-year, trading at 27.7x P/E. Similar headwinds, similar execution.

Industry headwinds are real:

  • Medicare reimbursement cuts (potential 15% reduction on hundreds of tests)
  • Labor inflation (phlebotomist/technician wage pressure)
  • COVID normalization (structural headwind, mostly absorbed)

But DGX and LH are trading at 24-28x P/E and up double-digits. QDEL is at 7.7x and down 42%. Either QDEL is uniquely broken, or it's mispriced relative to peers.

The difference: QDEL had the one-time ERP hit. DGX and LH didn't. The Street is treating the FCF miss as structural. Insiders are treating it as transitory.

The Insider Buying Signal

Why insider buying at crash lows matters:

Insiders have full visibility into Q1 2026 performance (we're mid-February). If the business were deteriorating, they wouldn't be buying. The CEO increased his position by 36%. The CFO — who is leaving in 4.5 months — bought $80K the same day he filed retirement, increasing his position by 49%.

Busky's purchase is the cleanest signal. He has no long-term incentive alignment (he's retiring). He has full visibility into financials. And he's betting personal cash on the recovery.

What they see that the market doesn't:

  • ERP costs behind them (completed Q3 2025, verified in 8-K)
  • Q1 2026 trending in-line or better
  • FCF inflection real (working capital normalization, capex moderation)
  • Valuation at 7.7x P/E with 25% SI = asymmetric setup

Insider buying doesn't guarantee upside. But at 10-year lows, after a 33% crash, with coordinated C-suite and board buying — it's a signal.

The Setup

Bull case:

  • FCF inflection: -$77M (2025) → $120-160M (2026) → higher (2027+)
  • Core business growing: Labs +6%, TRIAGE +9%, margin expansion 22% → 23.3%
  • Insider buying: $568K coordinated at crash lows (verified Form 4s)
  • Valuation: 7.7x P/E vs peers 24-28x
  • Short interest: 25% creates squeeze potential
  • Technicals: RSI 28, oversold, capitulation volume

Bear case:

  • Industry headwinds: reimbursement cuts, labor inflation
  • FCF guidance missed Street by $280M (midpoint)
  • CFO departure during distress (though he's buying)
  • Diagnostic peers also face headwinds (sector-wide issue)
  • QDEL has structural differences (smaller, COVID-exposed, recent merger)

Conviction: HIGH

  • Multiple independent signals converge (insider buying, FCF inflection, valuation dislocation)
  • Primary source verification (ERP completion in 8-K, not just management commentary)
  • Cleanest insider signal: retiring CFO buying with personal capital

Catalyst timeline:

  • Q1 2026 earnings (May 6): First quarter post-ERP, FCF inflection proof point
  • FY2026 progress: If FCF tracks toward $120-160M guide, valuation gap closes
  • Short squeeze: 25% SI with 10.4 days to cover — any positive catalyst accelerates

Risks:

  • FCF guide misses again (ERP wasn't the only issue)
  • Industry reimbursement cuts hit harder than expected
  • Macro weakens diagnostics demand
  • CFO replacement is weak (search underway)
  • Valuation gap is justified (QDEL structurally different from DGX/LH)

Position sizing: 3-4% (40% alpha × HIGH conviction = 1.5× multiplier)

Conclusion

The Feb 13 CFO retirement 8-K is low-signal. The Feb 13 insider buying is high-signal.

CEO, CFO, and board bought $568K at 10-year lows, two days after a 22% crash. The CFO bought $80K the same day he filed retirement. They see the FCF trough and the recovery. The market is pricing collapse. Insiders are betting on inflection.

At 7.7x P/E with Labs growing, TRIAGE growing, margins expanding, and FCF set to improve $200M+ (verified as one-time ERP hit in 8-K), the risk/reward favors the insiders.

Sources: